Some Aspects of Fake and Counterfeiting
of Drugs: Sudan Case
Volume 1 - Issue 5
Abdeen Mustafa Omer*
-
Author Information
Open or Close
- Occupational Health Administration, Ministry of Health, Khartoum, Sudan
*Corresponding author:
Abdeen Mustafa Omer, Occupational Health Administration, Ministry of Health, Khartoum, Sudan
Received:September 02, 2018; Published: September 10, 2018
DOI: 10.32474/LOJNHC.2018.01.000125
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
The strategy of price liberalisation and privatisation had been implemented in Sudan over the last decade, and has had a
positive result on government deficit. The investment law approved recently has good statements and rules on the above strategy in
particular to pharmacy regulations. Under the pressure of the new privatisation policy, the government introduced radical changes
in the pharmacy regulations. To improve the effectiveness of the public pharmacy, resources should be switched towards areas
of need, reducing inequalities and promoting better health conditions. Medicines are financed either through cost sharing or full
private. The role of the private services is significant. A review of reform of financing medicines in Sudan is given in this study. Also,
it highlights the current drug supply system in the public sector, which is currently responsibility of the Central Medical Supplies
Public Corporation (CMS). In Sudan, the researchers did not identify any rigorous evaluations or quantitative studies about the
impact of drug regulations on the quality of medicines and how to protect public health against counterfeit or low quality medicines,
although it is practically possible. However, the regulations must be continually evaluated to ensure the public health is protected
against by marketing high quality medicines rather than commercial interests, and the drug companies are held accountable for
their conduct.
Keywords: Counterfeits Medicines; Drug Importers; Quality of Medicines; Regulatory Authorities
Abbreviations: CMSPO: Central Medical Supplies Public Organisation; CRC: Centre of Regulation and Competition; DAP: Drug
Action Programme; DOP: Department of Pharmacy; FGDOP: Federal General Directorate of Pharmacy; FMOH: Federal Ministry of
Health; FPPB: Federal Pharmacy and Poison Board; GMP: Good Manufacturing Practice; KS: Khartoum State; MOAR: Ministry of
Animal Resources; MOH: Ministry of Health; NGOs: Non Governmental Organisations; NDP: National Drug Policy; RDFs: Revolving
Drug Funds; SPSS: Statistical Package for Social Sciences; UK: United Kingdom; USA: United States of America; WHO: World Health
Organisation
Abstract|
Introduction|
Aims and Objectives|
Medicines Legislation Framework in Sudan|
Sudan Medicines’ Quality Measures|
Discussions|
Conclusion and Recommendation|
References|